These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. Shi Y, Hu J, Geng J, Hu T, Wang B, Yan W, Jiang Y, Li J, Liu S. Biomed Pharmacother; 2018 Nov; 107():1556-1563. PubMed ID: 30257374 [Abstract] [Full Text] [Related]
12. Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. Li M, Shu X, Xu H, Zhang C, Yang L, Zhang L, Ji G. J Transl Med; 2016 Aug 05; 14(1):237. PubMed ID: 27495782 [Abstract] [Full Text] [Related]
13. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. Yue SJ, Liu J, Wang AT, Meng XT, Yang ZR, Peng C, Guan HS, Wang CY, Yan D. Am J Physiol Endocrinol Metab; 2019 Jan 01; 316(1):E73-E85. PubMed ID: 30422704 [Abstract] [Full Text] [Related]
15. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota. Lyu Y, Zhang Y, Yang M, Lin L, Yang X, Cheung SCK, Shaw PC, Chan PKS, Kong APS, Zuo Z. Life Sci; 2019 Oct 15; 235():116818. PubMed ID: 31473193 [Abstract] [Full Text] [Related]
18. Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. Jia Y, Xu B, Xu J. Pharm Biol; 2017 Dec 15; 55(1):510-515. PubMed ID: 27937081 [Abstract] [Full Text] [Related]